The IDCRC is a collaboration of world-renowned leaders in infectious diseases, immunology, and clinical research from leading academic institutions and affiliates across the country. The IDCRC works through a flexible, sustaining structure to advance new countermeasures and approaches to product development, implement efficient clinical study/trial designs, promote the integration of special and underserved populations in IDCRC research across the human lifespanand support exceptional career development and mentoring of future leaders in infectious diseases clinical research. The consortium's collective experience and access to diverse populations give it the ability to evaluate new vaccines and therapies for infectious diseases. 

We serve as a hub with the VTEUs and NIAID to integrate, facilitate and build IDCRC research priorities and processes. The goal of the IDCRC is to support the planning and implementation of infectious diseases clinical research that efficiently addresses the scientific priorities of NIAID. The consortium has two arms – the Leadership Group (LG) and the Vaccine and Treatment Evaluation Units (VTEU sites), both funded by the NIAID.  We foster collaborative team science with NIAID, the VTEUs and other partners to best address the NIAID infectious diseases priorities. 




IDCRC Leadership Group

Emory University School of Medicine

University of Maryland Baltimore

Baylor College of Medicine

Cincinnati Children’s Hospital Medical Center

FHI 360

Fred Hutch

University of Alabama School of Medicine

Johns Hopkins School of Medicine

Vanderbilt University Medical Center

University of Washington

IDCRC Vaccine & Treatment Evaluation Units (VTEUs)

COVID-19 Prevention Network

The CoVPN was established by merging four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network; the HIV Prevention Trials Network; the Infectious Diseases Clinical Research Consortium; and the AIDS Clinical Trials Group.

More about the CoVPN
COVID-19 Prevention Network launches two research studies evaluating monoclonal antibodies